Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 86 of 533 for:    Taste Disorders AND taste

Human Oral Detection of Glucose Olygomers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02589353
Recruitment Status : Recruiting
First Posted : October 28, 2015
Last Update Posted : March 7, 2019
Sponsor:
Information provided by (Responsible Party):
Juyun Lim, Oregon State University

Brief Summary:
Although salivary contents play a major role in the early stage of food digestion process, their role in taste perception of glucose polymers is essentially unknown. It is hypothesized that the differences in salivary contents, more specifically salivary amylase concentration and activity, influence taste perception of glucose polymers and ultimately eating behavior, which is related to risks in various diseases. The current project is designed to investigate 2 aims. Aim 1 will investigate the variation in salivary contents across individuals and its role in taste perception of glucose polymers. Aim 2 will focus on the role of salivary contents in food liking and disliking.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Acarbose Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Role of Salivary Contents in Taste Perception of Starch and Its Hydrolysis Products
Actual Study Start Date : April 21, 2017
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Acarbose

Arm Intervention/treatment
Experimental: Acarbose
Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
Drug: Acarbose
Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)




Primary Outcome Measures :
  1. Detection of glucose polymers in the presence of acarbose [ Time Frame: up to 5 years ]
    There is only one outcome measure, that is the detection of glucose polymers. Subjects will be asked to discriminate a target sample (glucose polymers). Three samples will be applied using cotton swabs on the subjects' tongue (one at a time): 2 blanks (water + acarbose) and 1 target stimuli (glucose polymer solution + acarbose). Subjects will be asked to identify the target sample. The number of subjects who correctly identify the target stimuli will be counted and will be statistically analyzed to determine whether glucose polymer can be detected without the confounding effect of salivary alpha amylase hydrolysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • self-reported healthy adults between the ages of 18-60 who are fluent in English.

Exclusion Criteria:

  • adults 61 years old and above
  • smokers
  • pregnant women
  • taking any prescription pain/ insulin medication
  • has a history of taste or smell loss or other oral disorders (e.g., burning mouth syndrome)
  • has current oral lesions, canker sores, or piercings
  • has a history of food allergy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02589353


Contacts
Layout table for location contacts
Contact: Juyun Lim 541-737-6507 juyun.lim@oregonstate.edu

Locations
Layout table for location information
United States, Oregon
Department of Food Science and Technology Recruiting
Corvallis, Oregon, United States, 97331
Contact: Juyun Lim    541-737-6507    juyun.lim@oregonstate.edu   
Sponsors and Collaborators
Oregon State University
Investigators
Layout table for investigator information
Principal Investigator: Juyun Lim Oregon State University

Layout table for additonal information
Responsible Party: Juyun Lim, Associate Professor, Oregon State University
ClinicalTrials.gov Identifier: NCT02589353     History of Changes
Other Study ID Numbers: IRB # 5373
First Posted: October 28, 2015    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Acarbose
Glycoside Hydrolase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs